CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade iBio, Inc. - IBIO CFD

    1.3389
    4.29%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0322
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.001
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    ENGlobal Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.3989
    Open* 1.3689
    1-Year Change* 106.16%
    Day's Range* 1.2889 - 1.4189
    52 wk Range 0.25-2.60
    Average Volume (10 days) 312.69K
    Average Volume (3 months) 10.04M
    Market Cap 7.49M
    P/E Ratio -100.00K
    Shares Outstanding 28.10M
    Revenue 50.00K
    EPS -2.05
    Dividend (Yield %) N/A
    Beta -3.16
    Next Earnings Date Feb 12, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 1.3389 -0.0200 -1.47% 1.3589 1.4189 1.2689
    Dec 7, 2023 1.3989 -0.1100 -7.29% 1.5089 1.5389 1.3889
    Dec 6, 2023 1.4889 0.1400 10.38% 1.3489 1.5889 1.2689
    Dec 5, 2023 1.2889 -0.2100 -14.01% 1.4989 1.5989 1.2789
    Dec 4, 2023 2.6289 -0.5200 -16.51% 3.1489 3.2189 2.5989
    Dec 1, 2023 2.9389 0.1800 6.52% 2.7589 3.0389 2.7589
    Nov 30, 2023 3.2289 -0.3000 -8.50% 3.5289 3.6489 3.2189
    Nov 29, 2023 3.7089 -0.1771 -4.56% 3.8860 4.1689 3.5589
    Nov 28, 2023 0.1943 -0.0536 -21.62% 0.2479 0.2504 0.1919
    Nov 27, 2023 0.2808 0.0030 1.08% 0.2778 0.2980 0.2689
    Nov 24, 2023 0.2736 0.0087 3.28% 0.2649 0.2753 0.2525
    Nov 22, 2023 0.2639 0.0050 1.93% 0.2589 0.2749 0.2459
    Nov 21, 2023 0.2645 0.0186 7.56% 0.2459 0.2645 0.2459
    Nov 20, 2023 0.2579 0.0009 0.35% 0.2570 0.2591 0.2459
    Nov 17, 2023 0.2579 -0.0100 -3.73% 0.2679 0.2679 0.2519
    Nov 16, 2023 0.2605 -0.0089 -3.30% 0.2694 0.2739 0.2435
    Nov 15, 2023 0.2743 -0.0034 -1.22% 0.2777 0.2777 0.2620
    Nov 14, 2023 0.2788 0.0079 2.92% 0.2709 0.2834 0.2507
    Nov 13, 2023 0.2858 0.0134 4.92% 0.2724 0.2858 0.2573
    Nov 10, 2023 0.2733 -0.0055 -1.97% 0.2788 0.2788 0.2459

    iBio, Inc. Events

    Time (UTC) Country Event
    Monday, February 12, 2024

    Time (UTC)

    22:27

    Country

    US

    Event

    Q2 2024 Ibio Inc Earnings Release
    Q2 2024 Ibio Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total revenue 0 1.884 2.371 1.638 2.018
    Revenue 0 1.884 2.371 1.638 2.018
    Total Operating Expense 29.343 31.581 33.482 15.641 17.806
    Selling/General/Admin. Expenses, Total 18.451 19.994 21.74 11.067 12.01
    Research & Development 10.327 9.827 9.989 3.573 5.474
    Operating Income -29.343 -29.697 -31.111 -14.003 -15.788
    Interest Income (Expense), Net Non-Operating 0.032 0.177 -2.314 -2.451 -1.825
    Other, Net 0 0.007 10.212 0.01 0.016
    Net Income Before Taxes -29.311 -29.513 -23.213 -16.444 -17.597
    Net Income After Taxes -29.311 -29.513 -23.213 -16.444 -17.597
    Minority Interest 0 0.001 0.006 0.005 0.004
    Net Income Before Extra. Items -29.311 -29.512 -23.207 -16.439 -17.593
    Net Income -65.01 -50.303 -23.207 -16.439 -17.593
    Income Available to Common Excl. Extra. Items -29.311 -29.6 -23.467 -38.26 -17.853
    Income Available to Common Incl. Extra. Items -65.01 -50.391 -23.467 -38.26 -17.853
    Diluted Net Income -65.01 -50.391 -23.467 -38.26 -17.853
    Diluted Weighted Average Shares 12.245 8.721 7.8248 2.5118 0.75704
    Diluted EPS Excluding Extraordinary Items -2.39371 -3.39411 -2.99905 -15.2321 -23.5826
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -2.34757 -3.19229 -2.99905 -15.2321 -23.5826
    Total Adjustments to Net Income 0 -0.088 -0.26 -21.821 -0.26
    Depreciation / Amortization 0.291 0.298 0.322
    Cost of Revenue, Total 1.462 0.703
    Gross Profit 0.909 0.935
    Unusual Expense (Income) 0.565 1.76
    Total Extraordinary Items -35.699 -20.791
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Cost of Revenue, Total
    Gross Profit
    Total Operating Expense 4.965 6.169 10.573 7.636 10.453
    Selling/General/Admin. Expenses, Total 2.609 3.525 7.229 5.088 5.131
    Research & Development 2.356 2.644 2.779 2.548 3.562
    Operating Income -4.965 -6.169 -10.573 -7.636 -10.453
    Interest Income (Expense), Net Non-Operating 0.033 -0.11 0.01 0.099 0.066
    Other, Net 0 0 0 0
    Net Income Before Taxes -4.932 -6.279 -10.563 -7.537 -10.387
    Net Income After Taxes -4.932 -6.279 -10.563 -7.537 -10.387
    Minority Interest 0 0 0 0 0
    Net Income Before Extra. Items -4.932 -6.279 -10.563 -7.537 -10.387
    Net Income -6.033 -7.294 -33.553 -18.13 -17.054
    Total Adjustments to Net Income 0 0 0 0 0
    Income Available to Common Excl. Extra. Items -4.932 -6.279 -10.563 -7.537 -10.387
    Income Available to Common Incl. Extra. Items -6.033 -7.294 -33.553 -18.13 -17.054
    Diluted Net Income -6.033 -7.294 -33.553 -18.13 -17.054
    Diluted Weighted Average Shares 17.204 13.184 9.807 8.842 8.727
    Diluted EPS Excluding Extraordinary Items -0.28668 -0.47626 -1.07709 -0.85241 -1.19021
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.28668 -0.47626 -1.01948 -0.85241 -0.98854
    Unusual Expense (Income) 0 0 0.565 1.76
    Total Extraordinary Items -1.101 -1.015 -22.99 -10.593 -6.667
    • Annual
    • Quarterly
    2023 2022 2021 2020 2019
    Total Current Assets 26.259 45.07 104.597 61.748 4.808
    Cash and Short Term Investments 4.301 33.521 96.974 55.112 4.421
    Cash 77.404 55.112 4.421
    Total Receivables, Net 0.204 6.1 5.526 5.624 0.097
    Accounts Receivable - Trade, Net 0 1 0.426 0.075 0.097
    Total Inventory 3.9 0.027 0.798
    Prepaid Expenses 0.664 1.549 2.07 0.214 0.29
    Total Assets 41.207 99.406 146.968 94.189 30.586
    Property/Plant/Equipment, Total - Net 7.551 41.755 34.739 31.273 24.38
    Intangibles, Net 5.388 4.851 0.952 1.144 1.374
    Other Long Term Assets, Total 0.303 6.099 0.024 0.024 0.024
    Total Current Liabilities 21.582 30.436 6.645 5.236 3.458
    Accounts Payable 1.849 4.264 2.254 1.759 1.001
    Accrued Expenses 4.423 3.865 3.001 1.105 0.965
    Notes Payable/Short Term Debt 12.937 0 0.6 0.261 0
    Current Port. of LT Debt/Capital Leases 0.432 22.207 0.367 0.301 0.213
    Other Current Liabilities, Total 1.941 0.1 0.423 1.81 1.279
    Total Liabilities 25.826 35.921 38.383 37.571 28.123
    Total Long Term Debt 0.592 0.03 31.755 32.346 24.671
    Capital Lease Obligations 0.351 0.03 31.755 32.007 24.671
    Minority Interest 0 -0.017 -0.011 -0.006
    Total Equity 15.381 63.485 108.585 56.618 2.463
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.02 0.009 0.217 0.14 0.02
    Additional Paid-In Capital 304.301 287.619 282.058 206.931 108.295
    Retained Earnings (Accumulated Deficit) -288.94 -223.93 -173.627 -150.42 -105.821
    Other Equity, Total 0 -0.213 -0.063 -0.033 -0.031
    Total Liabilities & Shareholders’ Equity 41.207 99.406 146.968 94.189 30.586
    Total Common Shares Outstanding 20.3101 8.72716 8.71492 5.60284 0.8061
    Total Preferred Shares Outstanding 0 0
    Property/Plant/Equipment, Total - Gross 8.155 45.327 43.488 37.899
    Accumulated Depreciation, Total -0.604 -3.572 -8.749 -6.626
    Long Term Debt 0.241 0 0.339
    Short Term Investments 0 10.845 19.57
    Note Receivable - Long Term 1.706 1.631 6.656
    Cash & Equivalents 4.301 22.676
    Other Liabilities, Total 3.652 5.455
    Other Current Assets, Total 21.09
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 23.022 26.259 27.093 38.235 63.565
    Cash and Short Term Investments 1.461 4.301 6.562 9.625 17.486
    Cash
    Short Term Investments 0 0 5.929 7.599
    Total Receivables, Net 0 0.204 1.242 7.739 6.155
    Accounts Receivable - Trade, Net 0 0.07 0.97 1.055
    Total Inventory
    Prepaid Expenses 0.451 0.664 0.921 0.414 1.146
    Total Assets 37.678 41.207 44.386 51.8 84.564
    Property/Plant/Equipment, Total - Net 7.242 7.551 7.822 7.864 7.267
    Property/Plant/Equipment, Total - Gross 8.078 8.155 8.193 8.047 3.888
    Accumulated Depreciation, Total -0.836 -0.604 -0.371 -0.183 -0.085
    Intangibles, Net 5.383 5.388 5.393 5.398 6.013
    Note Receivable - Long Term 1.728 1.706 0.775 0 1.65
    Other Long Term Assets, Total 0.303 0.303 3.303 0.303 6.069
    Total Current Liabilities 20.708 21.582 22.276 27.775 32.199
    Accounts Payable 1.911 1.849 2.013 4.002 4.807
    Accrued Expenses 3.791 4.423 4.198 5.316 2.778
    Notes Payable/Short Term Debt 12.625 12.937 13.7 16.011 22.201
    Current Port. of LT Debt/Capital Leases 0.442 0.432 0.421 0.411 0.303
    Other Current Liabilities, Total 1.939 1.941 1.944 2.035 2.11
    Total Liabilities 24.469 25.826 26.997 32.977 36.196
    Total Long Term Debt 0.477 0.592 0.705 0.813 0.576
    Long Term Debt 0.198 0.241 0.283 0.323
    Capital Lease Obligations 0.279 0.351 0.422 0.49 0.576
    Minority Interest
    Total Equity 13.209 15.381 17.389 18.823 48.368
    Common Stock 0.028 0.02 0.016 0.012 0.009
    Additional Paid-In Capital 307.867 304.301 300.28 294.591 290.642
    Retained Earnings (Accumulated Deficit) -294.686 -288.94 -282.907 -275.613 -242.06
    Other Equity, Total 0 0 -0.167 -0.223
    Total Liabilities & Shareholders’ Equity 37.678 41.207 44.386 51.8 84.564
    Total Common Shares Outstanding 27.6536 20.3101 15.8181 12.3683 9.00658
    Total Preferred Shares Outstanding
    Cash & Equivalents 1.461 4.301 6.562 3.696 9.887
    Long Term Investments
    Other Liabilities, Total 3.284 3.652 4.016 4.389 3.421
    Other Current Assets, Total 21.11 21.09 18.368 20.457 38.778
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -50.304 -23.213 -16.444 -17.597 -16.108
    Cash From Operating Activities -37.48 -30.064 -13.345 -13.975 -13.48
    Cash From Operating Activities 2.874 2.123 1.943 1.427 1.368
    Amortization 0.401 0.291 0.298 0.322 0.341
    Non-Cash Items 6.306 1.889 0.388 0.42 0.831
    Cash Interest Paid 1.045 2.446 2.372 1.903 1.917
    Changes in Working Capital 3.243 -11.154 0.47 1.453 0.088
    Cash From Investing Activities -5.127 -26.478 -1.154 -0.99 -1.079
    Capital Expenditures -11.63 -5.162 -1.154 -0.99 -1.079
    Cash From Financing Activities -6.125 78.835 65.192 3.453 22.406
    Financing Cash Flow Items -0.372 0.836 -2.17 2.3 0.968
    Issuance (Retirement) of Stock, Net 0.077 78.33 68.823 1.35 21.621
    Issuance (Retirement) of Debt, Net -5.83 -0.331 -1.461 -0.197 -0.183
    Foreign Exchange Effects -0.001 -0.002 -0.001 -0.001
    Net Change in Cash -48.732 22.292 50.691 -11.513 7.846
    Other Investing Cash Flow Items, Total 6.503 -21.316
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -58.977 -51.683 -18.13 -50.304 -33.25
    Cash From Operating Activities -25.466 -21.594 -13.959 -37.48 -25.977
    Cash From Operating Activities 0.664 0.476 0.284 2.874 2.119
    Amortization 0.121 0.116 0.067 0.401 0.333
    Non-Cash Items 21.932 20.906 1.422 6.306 3.173
    Cash Interest Paid 0.523 0.363 0.187 1.045 0.86
    Changes in Working Capital 10.794 8.591 2.398 3.243 1.648
    Cash From Investing Activities 7.015 -1.226 0.029 -5.127 -5.604
    Capital Expenditures -5.924 -6.125 -3.171 -11.63 -8.2
    Other Investing Cash Flow Items, Total 12.939 4.899 3.2 6.503 2.596
    Cash From Financing Activities -0.439 -1.903 1.141 -6.125 -6.115
    Financing Cash Flow Items -0.061 -0.061 -0.372 -0.372
    Issuance (Retirement) of Stock, Net 7.851 4.015 1.151 0.077 0.077
    Issuance (Retirement) of Debt, Net -8.229 -5.857 -0.01 -5.83 -5.82
    Foreign Exchange Effects 0.033
    Net Change in Cash -18.857 -24.723 -12.789 -48.732 -37.696

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    iBio, Inc. Company profile

    iBio is a biopharmaceutical company behind the FastPharming System that helps with drug development “from concept to clinic”.

    Headquartered in Texas, iBio was founded in 2008 and operates in biopharmaceuticals and bioprocessing segments along with its subsidiary, iBio CDMO LLC. 

    iBio’s main product is the FastPharming System, which has helped produce monoclonal antibodies, subunit vaccines, cytokines and other recombinant proteins, according to the company’s site. 

    iBio has also built the Glycaneering Development Services, which provides “greater control over the glycosylation of complex biopharmaceuticals''. 

    The company operates in the fields of oncology, fibrotic and infectious diseases. 

    The company’s development and manufacturing services deliver fast, scalable and sustainable solutions, enabling iBio to draw a licence agreement with Planet Biotechnology, and collaboration agreements with CC-Pharming Ltd, Safi BioSolutions and several other companies to develop therapeutic solutions.

    The company went public in 2020 on the NYSE American. iBio, Inc. stock trades under the ticker symbol IBIO.

    Check out the IBIO price history and today’s share value at Capital.com. Always stay on top of the latest price developments with our live IBIO stock chart.

    Industry: Construction & Engineering (NEC)

    11740 Katy Fwy
    Energy Tower Iii, 11Th Floor
    77079

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    XRP/USD

    0.63 Price
    -5.420% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Oil - Crude

    71.93 Price
    +0.620% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Gold

    1,999.31 Price
    -0.260% 1D Chg, %
    Long position overnight fee -0.0199%
    Short position overnight fee 0.0117%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    US100

    16,049.90 Price
    -0.160% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading